Brief: Scynexis Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Requirement
22/12/2025 13:20
Dec 22 (Reuters) - SCYNEXIS Inc SCYX.O: SCYNEXIS GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT Source text: ID:nGNX3P9RkR Further company coverage: SCYX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview